Dynavax NASDAQ: DVAX www.dynavax.com
Düsseldorf, DE · 258 employees on LinkedIn · 1 known investors
Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Founders & leadership
RS
Ryan SpencerChief Executive Officer
DN
David NovackPresident and Chief Operating Officer
RJ
Robert JanssenChief Medical Officer and Senior Vice President, Clinical Development
KM
Kelly MacDonaldChief Financial Officer
JC
Jeff CoonChief Human Resources Officer
DC
Donn CasaleChief Commercial Officer
AD
Andrew DavisChief Business Officer
Investors · 1
Competitors · 1
by search overlap
Companies competing with Dynavax NASDAQ: DVAX www.dynavax.com for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2013 | $223.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $599K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $404.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $595.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $595.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $720.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2008 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $207.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $119.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Dynavax NASDAQ: DVAX www.dynavax.com do?
- Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
- Who are Dynavax NASDAQ: DVAX www.dynavax.com's investors?
- Dynavax NASDAQ: DVAX www.dynavax.com's investors include Sanderling Ventures.
- Where is Dynavax NASDAQ: DVAX www.dynavax.com headquartered?
- Dynavax NASDAQ: DVAX www.dynavax.com is headquartered in Düsseldorf, DE.